Assist. Prof. Dr. Mai O.Kadry,National Research Center, Egypt
Dr. Mai Osman Mohamed Kadry is a distinguished biochemistry researcher at the Therapeutic Chemistry Department, National Research Centre, Egypt. With a Doctorate in Biochemistry from Cairo University (2016), her work focuses on oxidative injury, nanotoxicity, and cancer therapy. She has published extensively in high-impact journals on topics like antioxidant effects, stem cell therapies, and metabolic disorders. Dr. Kadry has also contributed to academia, teaching pharmacognosy at 6th October University. Skilled in advanced techniques like PCR, HPLC, and ELISA, she actively participates in groundbreaking nanobiotechnology research projects. Dr. Kadry is committed to advancing therapeutic strategies for critical diseases. 📚🧬
Publication Profile
Scopus
Academic and Professional Experience 🌟🎓
Assist. Prof. Dr. Mai O. Kadry has accumulated valuable experience in academia and research. She served as a pharmacognosy instructor at the Faculty of Pharmacy, 6th October University, Cairo, Egypt (2003–2004), where she effectively delivered courses on natural products and their therapeutic applications. Dr. Kadry also contributed as a staff member focused on development and quality enhancement, aligning with the standards of the National Commission for Academic Accreditation. Her dedication to education and quality assurance reflects her commitment to fostering academic excellence and professional growth in pharmaceutical sciences. 📚🔬
Educational Background 🎓📘
Assist. Prof. Dr. Mai O. Kadry boasts a strong academic foundation in pharmaceutical sciences. She earned her Doctorate in Biochemistry from the Faculty of Pharmacy, Cairo University, in 2016, with a thesis on the “Amelioration of Nano-Sized Titanium Dioxide-Induced Oxidative Injury in Mice by Some Antioxidants.” She obtained her Master’s degree in Pharmaceutical Sciences from Helwan University in 2008, focusing on the synergistic effects of phytic and catechin on carbon tetrachloride-induced damage in rats. Dr. Kadry completed her B.Sc. in Pharmaceutical Science at Ain Shams University in 2003, graduating with honors. She also attended English language schools, enhancing her global communication skills. 🌟🔬
Training 🧬📚
Assist. Prof. Dr. Mai O. Kadry has undergone extensive training in various scientific disciplines. She completed courses in Biostatistics (November 2016) and Bioinformatics (January 2017) at the National Research Centre. Earlier, she gained expertise in Scientific Typewriting Bases (March 2007) and Occupational Health and Safety (June 2009). Additionally, she mastered Protein Electrophoresis through a four-month course in 2006. Dr. Kadry enhanced her practical skills with hands-on training at Al-Borg Clinical Laboratory, focusing on PCR techniques for detecting HBV and HCV at the Theodor Bilharz Research Institute. Her comprehensive training equips her with valuable laboratory and analytical skills. 🔬🧪
Research Focus 🧪🧠🧬
Assist. Prof. Dr. Mai O. Kadry focuses on cutting-edge biomedical research, emphasizing toxicity, cancer therapy, and molecular biology. Her work explores inflammatory mediators, DNA damage, and therapeutic approaches in liver, brain, and nephrotoxicity contexts. She investigates autophagy, necroptosis, and novel strategies like resveratrol nano-formulations for ovarian cancer. Dr. Kadry also studies molecular pathways in gastric and prostate cancers, including miRNA-lncRNA signaling and CRISPR-Cas9 applications. Other interests involve genetic mutations in leukemia, drug-delivery systems, and nanotechnology for breast cancer. Her contributions bridge diagnostics, therapeutic innovations, and cellular mechanisms in oncology and toxicology. 🔬✨
Publication Top Notes
- Inflammatory mediators-induced DNA damage in liver and brain injury: Therapeutic approach of 5-Methoy-N-acetyltryptamine – 2024, Toxicology Reports 🧬
- Necroptosis and autophagy in cisplatinum-triggered nephrotoxicity: Novel insights regarding prognostic and diagnostic potential – 2024, Toxicology Reports 🧪
- Resveratrol-based nano-formulations as a therapeutic strategy for ovarian carcinoma: Autophagy and SIRT-1 signaling – 2024, Cancer Nanotechnology 💊
- miR-122-IGF-1R signaling allied with dysregulated lncRNA MALAT-1 in gastric carcinoma – 2024, Toxicology Reports 🔬 (Cited by: 1)
- Reciprocal crosslink among MeCP2/BDNF/CREB signaling in autism spectrum disorder – 2024, Toxicology Reports 🧠
- CRISPR-Cas9 genome and lncRNAs for prostate cancer therapy via liposomal compounds – 2024, PLoS ONE 🧬 (Cited by: 1)
- Collaboration of Hprt/K-RAS/c-Myc mutation in T-lymphocytic leukemia oncogenesis – 2024, Future Science OA 🧪 (Cited by: 1)
- Thioctic acid shield against lipopolysaccharide depression and endoplasmic stress – 2024, Future Science OA 🧫
- Titanium dioxide nanostructure-loaded Adriamycin in breast cancer therapy – 2024, Future Science OA 🎗️ (Cited by: 1)
- Alleviation of doxorubicin adverse effects via drug-delivery systems – 2024, Therapeutic Delivery 🚑